Heron Therapeutics, Inc.
HRTX
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -4.38% | -4.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.38% | -4.61% | |||
| Cost of Revenue | 19.14% | -19.92% | |||
| Gross Profit | -13.34% | 2.89% | |||
| SG&A Expenses | 4.13% | 7.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.64% | -2.35% | |||
| Operating Income | -151.90% | -24.42% | |||
| Income Before Tax | -190.36% | -28.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -190.36% | -28.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -190.36% | -28.06% | |||
| EBIT | -151.90% | -24.42% | |||
| EBITDA | -127.69% | -22.07% | |||
| EPS Basic | -190.12% | -28.03% | |||
| Normalized Basic EPS | -190.65% | -52.86% | |||
| EPS Diluted | -300.00% | -58.16% | |||
| Normalized Diluted EPS | -215.48% | -63.00% | |||
| Average Basic Shares Outstanding | 0.35% | 0.22% | |||
| Average Diluted Shares Outstanding | -21.79% | 28.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||